ProQR Therapeutics (PRQR) Non-Current Debt (2021 - 2023)

ProQR Therapeutics' Non-Current Debt history spans 3 years, with the latest figure at $4.6 million for Q4 2023.

  • For Q4 2023, Non-Current Debt rose 5.98% year-over-year to $4.6 million; the TTM value through Dec 2023 reached $4.6 million, up 5.98%, while the annual FY2023 figure was $4.6 million, 3.14% up from the prior year.
  • Non-Current Debt for Q4 2023 was $4.6 million at ProQR Therapeutics, up from $4.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $45.0 million in Q4 2021 and bottomed at $4.4 million in Q4 2022.
  • The 3-year median for Non-Current Debt is $4.6 million (2023), against an average of $18.0 million.
  • The largest annual shift saw Non-Current Debt crashed 90.31% in 2022 before it rose 5.98% in 2023.
  • A 3-year view of Non-Current Debt shows it stood at $45.0 million in 2021, then crashed by 90.31% to $4.4 million in 2022, then rose by 5.98% to $4.6 million in 2023.
  • Per Business Quant, the three most recent readings for PRQR's Non-Current Debt are $4.6 million (Q4 2023), $4.4 million (Q4 2022), and $45.0 million (Q4 2021).